Regulatory T cells (Treg) are now well established as vital participants in maintaining self-tolerance and preventing autoimmunity. Tregs have already been shown to be effective in preventing graft-versus-host disease in clinical bone marrow transplantation, and numerous animal studies have suggested a therapeutic role for Treg in solid organ transplantation. Recent advances in Treg isolation and expansion have the field poised to perform trials of therapeutic Treg infusion in solid organ transplantation worldwide. An important component of these trials will be the detection of infused cells and the assessment of Treg activity after infusion.
INTRODUCTION
Regulatory T cells (Treg) are now well established as critical modulators of the immune system and are essential for preventing autoimmune diseases [1 & ]. The therapeutic potential of Treg has now been extensively explored in animal models, establishing a strong rationale for testing their potential efficacy in preventing autoimmunity as well as alloimmunity in humans [2] . Treg have already shown promise in preventing graft-versus-host disease in the setting of human bone marrow transplantation [3,4,5 & ]. Recent advances in ex-vivo expansion and manufacturing of polyclonally expanded Treg as well as donor-reactive Treg has made the infusion of clinically meaningful doses of Tregs feasible [6 & ]. Currently, there are multiple groups worldwide preparing to test Treg in the setting of solid organ transplantation in phase I/II trials with most studies planning dose escalation [7] .
Because these trials have been primarily designed to test safety, it is unlikely that they will yield efficacy data. Thus, much of the focus of the trials will be on mechanistic outcomes, such as detection of infused Treg, longevity of infused Treg, and their impact on the overall immune responses of the recipients.
In this review, we will discuss recent data on infused Treg migration to allografts and how these may inform our interpretation of biopsy specimens from clinical trials in humans. In addition, we will discuss recent advances in Treg identification, quantification of alloreactivity in the Treg pool, as well as functional assays that may help elucidate how the infusion of Treg impacts the immune system. These data will be particularly important to estimate the cell numbers required to significantly impact immune responses for subsequent efficacy trials.
INTERPRETATION OF TRANSPLANT BIOPSIES FOLLOWING REGULATORY T CELL THERAPY
A key question in Treg therapy is whether the administered Treg will migrate to the allograft, and how this will impact the histology of allograft biopsies. Treg appear to home similarly to T effector cells (Teff), including to sites of inflammation [8 & ,9 && ]. Because of the injury associated with surgery, as well as ischemia/reperfusion injury, allografts are known to recruit inflammatory cells as well as T lymphocytes. Another consideration is that, even in instances of spontaneous [9 && ] or induced transplant tolerance [10] , lymphocytes (including Treg) can be found within allografts. Foxp3 positive T cells have also been demonstrated in numerous human allograft biopsy studies [11, 12] .
In disparate rodent transplant models, infused Treg have been shown to migrate to allografts and colocalize with Teff cells [13,14 & ,15]. Treg/Teff ratios of greater than 1 : 3 have been shown to be associated with graft survival, whereas lower ratios tend to be associated with rejection [6 & ]. Antigen specificity is not required for localization, although graft-infiltrating cells appear to be enriched for allospecific Treg [16] . The preponderance of preclinical studies would therefore suggest that infused Treg should localize to the allograft. However, in preclinical models, Treg have been generally infused before or at the time of transplant and in the absence of generalized immunosuppression. For safety reasons, immunosuppression will clearly need to be administered in phase I/II trials, with an unknown impact on Treg migration and survival. Varied immunosuppressive regimens as well as timing of Treg administration are additional variables that may impact Treg migration.
An open question then is how allograft biopsies will appear and be interpreted in the upcoming clinical trials, especially in the early days to weeks following transplantation/Treg infusion. It is likely from preclinical data that infused Treg will migrate to the allograft and colocalize with potentially pathogenic T cells. With standard hematoxylin and eosin staining, it will be impossible to distinguish between Treg and Teff cells within the graft. Thus, protocol biopsies in the absence of clinical signals will need to be interpreted with caution, as a lymphocytic infiltrate may not necessarily indicate rejection. It is even possible that Treg will localize to areas, such as subendothelial areas, renal tubules, or bile ducts, which would conventionally contribute to a diagnosis of rejection. Foxp3 staining of biopsy specimens may help distinguish Treg from Teff; however, activated human Teff cells are known to transiently express Foxp3. Stable expression of Foxp3 is dependent on stable epigenetic modification of an area within the Foxp3 gene termed the Treg-specific demethylated region (TSDR). A PCR-based method for quantitating frequency of nonmethylated TSDR in peripheral blood samples has been recently devised [17] . This methodology correlates well with multiparameter flow cytometry in the quantitation of Treg/Teff ratios [18 && ]. This assay can also be used for tissue samples and may be of particular value in this setting. However, this assay does not give information at the single-cell level.
The interpretation of protocol biopsies will therefore be difficult in the absence of clinical indicators of rejection, especially in the early period after transplantation. The use of adjunctive modalities, such as Foxp3 staining, TSDR analysis, and potentially gene expression/proteomic analysis, and clinical correlation should be extremely informative, along with eventual clinical data.
IDENTIFICATION AND ENUMERATION OF REGULATORY T CELL
Seminal studies by Sakaguchi et al. [19] demonstrated that CD4 þ CD25 hi T cells contained suppressive activity. Treg were subsequently shown to express the intracellular protein Foxp3, providing a molecular marker for Treg. From a technical standpoint, however, CD25 staining as well as Foxp3 staining can be problematic and often do not generate distinct cell populations, making accurate
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Understanding modern assays of host immunity and alloreactivity will be critical to understanding their potential as therapeutics and evaluating their promise in Phase II/III trials. quantitation difficult. Importantly, a subsequent study [20] showed that Treg activity in peripheral blood was shown to primarily reside in the CD127 lo population, providing another maker to help separate Treg from Teff. More recently, the transcription factor Helios was correlated with Foxp3 expression, potentially discriminating natural Treg from induced Treg [21] . Like Foxp3, however, Helios also can be expressed transiently by proliferating Teff cells and its expression should be interpreted in context [22] . A more recent study [23 & ] demonstrated that approximately 10% of natural Treg clones do not express Helios, and therefore gating on Helios may miss a subpopulation of Treg. Nevertheless, it should serve as another marker to help separate most Treg from Teff, to improve quantitation. These additional markers may make identification more accurate. Overall, the accurate identification of Treg is not straightforward and any quantitation should be planned/reviewed carefully. TSDR analysis can help quantify Treg/Teff ratios but cannot be used at the single-cell level [18 && ].
The number of Teff and Treg in humans is not known but is a critical factor to consider for Treg therapy and subsequent detection of infused cells. A recent study [24] has estimated on the order of 166 Â 10 9 CD4 þ T cells in an average human, with approximately 13 Â 10 9 Treg. Thus, in a patient who has not had T-cell depletion as part of their immunosuppression, the infusion of even large numbers of Treg may not result in an appreciable rise in the overall numbers of Treg in the periphery. However, the pharmacokinetics and volume of distribution of exogenously manipulated/expanded Treg are not known.
In a trial of polyclonal Treg administered in newonset diabetics, the infusion of 10-30 Â 10 6 Treg/kg resulted in readily detectable increases in overall Treg number for as long as 2-4 months after infusion. These patients were lymphoreplete and did not receive any other treatment. It is likely, therefore, that increases in overall numbers of Tregs will be detectable in the peripheral blood of patients after infusion, if given similar numbers of Treg. Lymphodepletion prior to infusion with agents, such as antithymocyte globulin, will likely make lower doses detectable, as exemplified by the results in the extremely lymphodepleted context of bone marrow transplantation.
Notably, it will not be possible to distinguish between endogenous Treg and infused Treg in humans by using standard flow techniques. Additional techniques for labeling and/or tracking infused Treg have been developed but are beyond the scope of this review.
QUANTIFICATION OF ALLOREACTIVE REGULATORY T CELL/TEFF RATIOS
Preclinical studies of therapeutic Treg administration have shown that donor-reactive Treg are more potent at suppressing donor-specific proliferation in vitro and in preventing allograft rejection in vivo [6 & ]. Additional lines of evidence suggest that achieving a ratio of Treg/Teff of approximately 1 : 3 or greater is important in conferring protection [19] . Approximately 5-10% of Treg are reactive to a full major histocompatibility complex (MHC) mismatch [24] , similar to Teff. Thus, simply quantifying overall Teff and Treg numbers will not be sufficient to profile immunologic changes after Treg administration, as most of the quantified cells are likely to be less relevant.
Classically, mixed lymphocyte reaction assays have been used to measure proliferation or cytokine production in bulk cultures. Some assessment of donor-reactive Treg activity has been made by removing CD4 þ CD25 hi T cells, but this gives no indication as to the frequency of either Teff or Treg. ELISPOT assays can also be used to quantitate the frequency of donor-reactive Teff but is not useful for determining the frequency of donor-reactive Treg.
Recently, it has been shown that CD40L-stimulated B cells (sBc) can effectively drive proliferation of alloreactive Tregs [25 & ]. The use of CD40L-sBc as antigen presenting cells (APC) in mixed lymphocyte reaction (MLR) together with carboxyfluorescein succinimidyl ester (CFSE)-labeled responder cells allows simultaneous assessment of the proliferation of CD8 þ and CD4 þ Teff cells along with the proliferation of CD4 þ Treg (Fig. 1) . Proliferated cells that have diluted CFSE can be identified after 4 days of culture and their precursor frequency can be readily back calculated. The presence of Treg in the samples does not appear to affect the proliferation of the effector cells, as depletion of Treg from the sample did not increase Teff proliferation (unpublished data). This is likely due to the high expression of CD80, CD86, and human leukocyte antigen on the CD40L-sBc, which like activated dendritic cells can negate the suppressive effects of Treg on proliferation in vitro. Thus, this enhanced MLR can be used to quantify frequencies of donorreactive Tregs and effector T cells in Treg therapy trials and other trials aimed at boosting Tregs.
FUNCTIONAL ASSAYS FOR REGULATORY T CELL ACTIVITY
A defining characteristic of Treg is that they suppress the proliferation of Teff in response to activation. In general, Treg suppressive activity has been measured by progressive addition of Treg to responder Teff in vitro. Although Treg require stimulation through the T-cell receptor (TCR) to gain suppressive activity, once they are activated, they suppress in a nonspecific fashion, at least in vitro. It is important to distinguish assays that use nonspecific activation from those that use antigen as nonspecific activation. Assays that utilize nonspecific TCR activation, for example with anti-CD3/CD28 antibody-coated beads, will stimulate nearly all T cells and thus be a general measure of Teff/Treg activity. This type of assay will give no indication as to whether Treg activity for a specific antigen (e.g., alloantigen) has changed during the course of treatment. The administration of donor-reactive Treg, for example, could theoretically make only a small impact on the overall Treg activity of a patient but have a significant impact on the pool of donorreactive Treg.
Assessment of Treg activity against a specific donor requires the use of donor APC as stimulators. The addition of Treg at increasing ratios to Teff then can be utilized to determine the potency of suppression against a donor. Teff proliferation can be measured by using a variety of methods, such as CFSE dilution or incorporation of labeled nucleotides. It is important to note that donor-reactive Teff activity could also be changing over time in a given recipient because of the presence of the graft as well as immunosuppression/modulation; thus, we believe that it is important to use responder Teff from a single time point, ideally pretransplant. These assays tend to require relatively high cell numbers, are technically demanding, and can demonstrate significant variability.
Overall, recent advances in determining Treg and Teff frequencies as well as functional activity will hopefully provide some indication as to the doses of Treg that need to be administered to have a significant impact on overall Treg as well as donorreactive Treg populations. These data, in combination with specific tracking of the administered Treg, will establish pharmacokinetic and pharmacodynamic data that will help to guide the design of subsequent efficacy trials.
CONCLUSION
Trials evaluating the safety of Treg therapy in solid organ transplantation are poised to begin but will likely be underpowered or not designed to test efficacy. Thus, mechanistic data will play a large role in determining the impact of various doses of Treg and for the design of subsequent efficacy trials. Standard histological analysis of allograft biopsies may not be accurate due to anticipated infiltration of the graft by the infused Treg; therefore, additional analyses, such as immunohistochemistry to identify Treg versus non-Treg, will be required to characterize lymphocytic infiltrates. Additional information, such as cellular damage, recruitment of other inflammatory cells, and perhaps gene expression profiling and/or proteomics, will be useful to distinguish a 'benign' infiltrate from a pathogenic infiltrate. Regardless, caution should be exercised before treating a histologic finding in the absence of clinical correlates of rejection. Recent improvements in the identification of Treg, as well as assays to determine specificity of both Treg and Teff cells, will allow us to develop a pharmacokinetic profile of infused Treg and to understand the impact of dosing on overall Treg/ Teff ratios as well as on the donor-specific Treg/Teff ratios. Finally, new tracking technology will allow us to understand the relationship of the duration of survival of infused Treg with overall Treg/Teff ratios and allow the identification of 'infectious tolerance' in humans.
